Wellington Management Group
CCCC icon

Wellington Management Group’s C4 Therapeutics CCCC Stock Holding History

Wellington Management Group’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.06M Buy
+227,768
New +$779K ﹤0.01% 1740
2025
Q1 		– Sell
-283,705
Closed -$1.02M – 1958
2024
Q4 		$1.02M Sell
283,705
-2,336
-0.8% -$11.6K ﹤0.01% 1716
2024
Q3 		$1.63M Buy
286,041
+56,696
+25% +$341K ﹤0.01% 1596
2024
Q2 		$1.06M Buy
229,345
+32,236
+16% +$192K ﹤0.01% 1658
2024
Q1 		$1.61M Buy
+197,109
New +$1.53M ﹤0.01% 1574
2023
Q2 		– Sell
-124,810
Closed -$392K – 1833
2023
Q1 		$392K Sell
124,810
-9,971
-7% -$58.7K ﹤0.01% 1874
2022
Q4 		$795K Buy
134,781
+67,177
+99% +$557K ﹤0.01% 1691
2022
Q3 		$593K Buy
+67,604
New +$702K ﹤0.01% 1753

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wellington Management Group's CCCC Position: Q2 2026 in Review

Wellington Management Group opened a new position in C4 Therapeutics (CCCC) in Q2 2026: 227,768 shares worth $1.06M. The stake represents ﹤0.01% of the portfolio and ranks #1740 among its holdings. This is a return to the name: Wellington Management Group previously reported a position in CCCC as recently as Q4 2024.

Wellington Management Group first reported a position in CCCC in Q3 2022 and has held it in 8 quarters since. The position peaked at $1.63M in Q3 2024. 148 funds tracked by Wall St. Rank hold CCCC as of Q2 2026.

  • Wellington Management Group held 227,768 shares of C4 Therapeutics worth $1.06M as of Q2 2026.
  • C4 Therapeutics was a new Wellington Management Group position in Q2 2026.
  • C4 Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q2 2026, its #1740 holding.
  • Wellington Management Group first reported a position in C4 Therapeutics in Q3 2022 and has held it in 8 quarters since.
  • Wellington Management Group's C4 Therapeutics position peaked at $1.63M in Q3 2024.
  • 148 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2026.

Based on Wellington Management Group's 13F filing for Q2 2026, filed 14 Aug 2026.